PMC:7299399 / 8042-8603
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T38 | 1-4 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
| T39 | 9-16 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T43 | 32-42 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T44 | 383-391 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T45 | 511-527 | Disease | denotes | viral infections | http://purl.obolibrary.org/obo/MONDO_0005108 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T81 | 223-224 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T82 | 462-465 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T34 | 9-16 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T35 | 108-117 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T36 | 314-319 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T16 | 9-26 | http://purl.obolibrary.org/obo/GO_0006412 | denotes | protein synthesis |
| T17 | 17-26 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
| T18 | 511-527 | http://purl.obolibrary.org/obo/GO_0016032 | denotes | viral infections |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T40 | 81-528 | Sentence | denotes | The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 165 | 383-393 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 167 | 511-527 | Disease | denotes | viral infections | MESH:D001102 |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32519842-32259480-158463 | 202-204 | 32259480 | denotes | 27 |